Why Hematologists Get Sued: The Anticoagulant, the Missed Leukemia, and the Transfusion Reaction

By John Mahoney · June 2026 · 8 min read

Hematology is not a high-volume malpractice specialty, but the claims that come are concentrated, high-stakes, and unusually clean to prove or defend. The work lives in two failure modes: a management error on a powerful drug — an anticoagulant that was dosed too high, too low, or stopped at the wrong moment — and a diagnostic miss on a slow-burning blood cancer hiding in a routine lab result. Both are closed-loop failures: someone had the number on a screen and the system did not act on it. An attorney who screens these files by the visible injury alone will misread them, because the decisive fact is almost always a lab value and what was done with it. This guide explains where hematology liability actually lives, the cannot-miss failures behind it, and what separates a strong case from a weak one — for plaintiff and defense med-mal attorneys.

Disclaimer: This article is for informational purposes only and does not constitute legal advice. The patterns below draw on closed-claims and insurer datasets that span different eras and definitions; treat them as directional, verify against the controlling jurisdiction, and value any individual case on its own record.

The Frequency-and-Severity Reality

By frequency, hematology and oncology together sit in the middle band of malpractice risk — not as exposed as surgery or obstetrics, but well above the lowest-risk office specialties. Hematologists see a smaller absolute claim count than many fields simply because there are fewer of them, but the per-physician exposure is meaningful, and most physicians in cancer-care specialties face a claim during their career. The structural driver is that hematology patients are frequently very sick, on high-risk drugs, and dependent on a chain of lab-and-treatment decisions where a single dropped step can cause irreversible harm.

Severity is where hematology stands out. Because the harms are catastrophic — a fatal hemorrhage, a missed leukemia that progressed, a fatal hemolytic transfusion reaction, a stroke from under-anticoagulation — the cases that are paid tend to be paid large. Anticoagulation-related claims are among the most commonly reported drug-related malpractice categories in all of medicine, and delayed-cancer-diagnosis claims rank among the highest-severity allegation types across every specialty that touches oncology. The screening lesson is that hematology rewards depth over breadth: you will see fewer files, but the ones with a true closed-loop failure on an anticoagulant, a lab result, or a transfusion are among the most provable and most valuable in med-mal.

The Dominant Allegation Types

Hematology claims cluster into a medication-management group and a diagnostic group, plus a transfusion-safety thread that cuts across both:

• Anticoagulation management errors — the signature hematology claim. Over-anticoagulation causing major or fatal bleeding, under-anticoagulation causing a clot, stroke, or pulmonary embolism, and peri-procedural bridging failures where heparin or a DOAC was stopped or restarted incorrectly around surgery.
• Delayed or missed diagnosis of blood cancer — leukemia, lymphoma, or multiple myeloma not diagnosed in a timely way, very often because an abnormal CBC, peripheral smear, or protein study was not acted on. The highest-severity diagnostic exposure in the specialty.
• Transfusion errors and reactions — ABO-incompatible transfusion from a clerical or identification error, and reaction injuries such as TRALI (transfusion-related acute lung injury) and TACO (transfusion-associated circulatory overload).
• Failure to diagnose and treat heparin-induced thrombocytopenia (HIT) — failure to recognize a falling platelet count on heparin, continued heparin exposure, and the catastrophic thrombosis that follows.
• Chemotherapy and regimen dosing toxicity — wrong dose, wrong schedule, or failure to monitor and manage the toxicity of cytotoxic and targeted agents.

The structural point: hematology liability is overwhelmingly a closed-loop problem. In almost every category, a value existed — an INR, a platelet count, an abnormal CBC, a crossmatch, an antibody panel — and the negligence is in failing to recognize, communicate, or act on it. Any intake should be triaged first on which lab number was on the screen and what the record shows was done with it.

The Cannot-Miss Conditions and Failures

The conditions and failures that drive hematology litigation are:

• Major or fatal bleeding from over-anticoagulation. A supratherapeutic INR or an unmonitored DOAC that produced intracranial or gastrointestinal hemorrhage. The recurring failure is an out-of-range result that was not flagged, not communicated, and not corrected.
• Thrombosis or stroke from under-anticoagulation or a bridging error — anticoagulation stopped before a procedure and never restarted, a subtherapeutic dose, or a clot that the regimen should have prevented.
• Missed or delayed leukemia, lymphoma, or myeloma — an abnormal CBC, blast cells on a smear, an unexplained cytopenia, or a monoclonal protein that was not investigated or referred, allowing the cancer to progress to a worse stage.
• ABO-incompatible transfusion and acute transfusion reactions — the wrong unit given through an identification or clerical failure, or unrecognized TRALI/TACO — among the most preventable catastrophic events in medicine.
• Unrecognized heparin-induced thrombocytopenia — a platelet count that fell on heparin without the drug being stopped, leading to limb- or life-threatening thrombosis, plus chemotherapy dosing toxicity from a missed monitoring step.

For every one of these, the single most actionable screening question is the closed-loop question: what was the abnormal result, when did it appear, who was supposed to act on it, and does the record show that they did? A hematology claim very often turns on a result-notification, monitoring, or recall failure rather than a complex judgment call. The number was there; the system did not close the loop.

The Contributing Factors That Drive Payouts

Across hematology closed claims, the recurring contributing factors are:

• Medication management and monitoring — the costliest factor: supratherapeutic or subtherapeutic anticoagulation, missed INR or platelet trends, unmonitored DOAC therapy, and bridging errors around procedures. Anticoagulants are among the most litigated drug classes in all of medicine.
• Clinical judgment / diagnostic process — failure to act on an abnormal CBC, smear, or protein study, failure to refer or order a marrow biopsy, and the delay that lets a leukemia, lymphoma, or myeloma advance to a worse-prognosis stage.
• Systems and communication failures — abnormal results that were not flagged, not routed to the responsible clinician, or not communicated to the patient; transfusion identification and crossmatch breakdowns; and handoff gaps between the lab, the anticoagulation clinic, and the treating physician.
• Failure to recognize an evolving emergency — a falling platelet count on heparin (HIT), an acute transfusion reaction, or a chemotherapy toxicity that was not caught and managed in time.
• Documentation — incomplete records of result-notification, dosing rationale, monitoring intervals, consent for transfusion or chemotherapy, and the follow-up that was or was not done, which consistently decides whether a claim is paid.

Two of these are hematology-specific levers. The first is the result-notification record: in nearly every category, the line between a defensible file and a paid claim is whether the chart shows the abnormal value was seen, communicated, and acted on. The second is the systems-and-handoff record: anticoagulation and transfusion care run through teams, labs, and clinics, so the decisive question is often not whether the physician erred personally but whether the closed loop the system was supposed to provide actually closed. Documentation rarely creates liability here, but it almost always decides it.

Strong Case vs. Weak Case in Hematology Malpractice

The same factors grade the file, and the framing is useful to both sides.

What makes a hematology case strong (plaintiff) / dangerous (defense)

• A clearly out-of-range result — a supratherapeutic INR, a falling platelet count on heparin, blast cells on a smear, an unexplained cytopenia — that the record shows was available but never flagged, communicated, or acted on. A clean closed-loop failure.
• A blood cancer diagnosed at a stage where earlier action carried a materially better prognosis, supporting a strong loss-of-chance causation theory tied to a specific abnormal lab and date.
• A peri-procedural bridging error or under-anticoagulation that produced a documented, preventable thrombosis or stroke, with no recorded reason for the gap.
• An ABO-incompatible transfusion or unrecognized HIT traceable to an identification, crossmatch, or monitoring breakdown, with thin documentation of the safety steps that should have caught it.

What makes a hematology case weak (plaintiff) / defensible (defense)

• A documented monitoring plan with recorded result-notification and timely dose adjustment — the closed loop intact, even where a bad outcome still occurred.
• A bleeding or thrombotic event that was a disclosed, known risk of necessary anticoagulation, with documented informed consent and a defensible risk-benefit rationale, framing the harm as an accepted complication rather than negligence.
• A patient whose record shows non-adherence, missed INR checks, declined transfusion or treatment, or missed follow-up that drove the outcome.
• A transfusion or chemotherapy course administered to protocol with documented identification, crossmatch, monitoring, and consent, and an abnormal result that was promptly acted on.

Hematology rewards a fast triage to the lab record. On the management side, the case lives or dies on the monitoring trail and whether an out-of-range value was acted on. On the diagnostic side, it turns on the abnormal CBC, smear, or protein study and the loss-of-chance causation chain from that result to the delayed cancer. Whichever side you are on, grading the file means finding the decisive number, fixing the date it appeared, and pressure-testing the expert who will carry the closed-loop story.

Bottom Line

Hematologists do not get sued often, but when they do, the cases are concentrated, catastrophic, and unusually clean to litigate, because the decisive fact is almost always a lab value and what was done with it. The cannot-miss patterns are the supratherapeutic INR that was never corrected, the bridging gap that caused a clot, the abnormal CBC that hid a leukemia, the wrong unit of blood, and the platelet count that fell on heparin while the drug kept running. Every one of them is a closed-loop failure — the number was on the screen and the system did not act. Whether you are screening these cases for the plaintiff or defending them, triage first to the lab record, find the value and the date, and grade the file on whether the loop closed — not on the visible injury alone.

Questions? Contact us at [email protected] or (856) 979-6525

🔎 Screening a case in a different specialty? Browse all 70 specialty malpractice-risk guides in one place — Why Doctors Get Sued: Malpractice Risk by Specialty →